Fludarabine and Cytarabine as Continuous Infusion Plus G-CSF Priming for Elderly Patients With Resistant AML
Status:
Unknown status
Trial end date:
2007-10-01
Target enrollment:
Participant gender:
Summary
- To determine the feasibility of fludarabine and cytarabine as continuous infusion plus
granulocyte-colony stimulating factor priming for elderly patients with resistant acute
myeloid leukemia other than acute promyelocytic leukemia
- The feasibility will be evaluated in terms of toxicities, complete remission rate,
duration of complete remission, disease-free survival, and overall survival.